NGS-based RNA-seq Market by Products & Services, Technology, Application, End User - Global Forecast to 2022

  • ID: 4286395
  • Report
  • Region: Global
  • 157 Pages
  • Markets and Markets
1 of 5
The Global NGS-Based RNA-Seq Market is Projected to Reach USD 2.65 Billion by 2022 from USD 1.05 Billion in 2017, at a CAGR of 20.2%

FEATURED COMPANIES

  • 10x Genomics Inc. (U.S.)
  • BGI (China)
  • Gatc Biotech AG (Germany)
  • Genewiz Inc. (U.S.)
  • Hamilton Company (U.S.)
  • Illumina Inc. (U.S.)
  • MORE

NGS-based RNA-seq Market by Products & Services (Sample Preparation, Consumables, Bioinformatics), Technology (SBS, SMRT), Application (De novo, Transcriptome Epigenetics, Small RNA), End User (Research Centers, BioPharma Companies) - Global Forecast to 2022

The global NGS-based RNA-seq market is projected to reach USD 2.65 billion by 2022 from USD 1.05 billion in 2017, at a CAGR of 20.2%. Factors such as the advantages of RNA-seq over microarray technology, technological advancements in RNA-seq products, increasing number of RNA-seq grants, increasing number of research activities, and rapid growth in precision medicine are driving the growth of the NGS-based RNA-seq market. On the other hand, accuracy and standardization concerns in diagnostic testing and the lack of skilled technical personnel are some of the key factors limiting the growth of the market.

Market Segments

In 2016, the sequencing platforms and consumables segment is expected to account for the largest share of the market. The data analysis, storage, and management is expected to register the highest growth rate owing to its development of more efficient data analysis solutions and growing computational capabilities of data analytics providers. Research centers and academic & government institutes segment accounted for the largest share of the global market in 2016 due to the increasing focus of market players on providing efficient RNA-seq products & services for research applications and the growing number of government funding programs. However, the hospitals and clinics segment is expected to register the highest growth due to the growing number of agreements between companies and hospitals for the development of advanced tests and products catering to the specific needs of hospitals and clinics. Based on applications, the market is categorized into four segments, namely, de novo transcriptome assembly, expression profiling analysis, variant calling & transcriptome epigenetics, and small RNA sequencing. The expression profiling analysis segment accounted for the major share of the global NGS-based RNA-seq market owing to the technological advantages of expression profiling applications.

Largest and Fastest Geographical Market

Geographically, the NGS-based RNA-seq market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2016, followed by Europe and Asia-Pasific. However, Asia-Pacific is expected to register the highest growth rate during the forecast period from 2017 to 2022, owing to focus on R&D activities and the low cost of NGS products & services in this region.

Breakdown of supply-side primary interviews: by company type, designation, and region:

  • By Company Type: Tier 1 - 33%, Tier 2 - 50% and Tier 3 - 17%
  • By Designation: C level - 35%, Director level - 25%, Others - 40%
  • By Region: North America - 24%, Europe - 19%, APAC - 33%, RoW - 24%

Growth Strategies

The global NGS-based RNA-seq market is highly competitive, with a large number of global and local players. In 2016, the market was dominated by Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Pacific Biosciences of California, Inc. (U.S.). Product launches, agreements, and partnerships were the major strategies adopted by market players to achieve growth in the market.

Research Coverage

This report studies the NGS-based RNA-seq market based on product & service, application, technology, and end user. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.

Reasons to Buy the Report

From an insights perspective, this research report has focused on various levels of analysis-industry trends, market share analysis of top ten players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the NGS-based RNA-seq market, and high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product portfolios and services offered by the major players in the NGS-based RNA-seq market. The report analyzes the NGS-based RNA-seq market based on product & service, application, technology, end user, and region
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and product launches in the NGS-based RNA-seq market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various NGS-based RNA-seq products and services across geographies
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the NGS-based RNA-seq market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products and services, distribution networks, and manufacturing capabilities of leading players in the NGS-based RNA-seq market
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 10x Genomics Inc. (U.S.)
  • BGI (China)
  • Gatc Biotech AG (Germany)
  • Genewiz Inc. (U.S.)
  • Hamilton Company (U.S.)
  • Illumina Inc. (U.S.)
  • MORE

1 Introduction
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Geographic Scope
           1.3.3 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology
    2.1 Research Methodology Steps
    2.2 Research Design
    2.3 Secondary and Primary Research Methodology
           2.3.1 Secondary Research
                    2.3.1.1 Key Data From Secondary Sources
           2.3.2 Primary Data
                    2.3.2.1 Key Data From Primary Sources
                    2.3.2.2 Key Industry Insights
    2.4 Market Size Estimation
           2.4.1 Bottom-Up Approach
           2.4.2 Top-Down Approach
    2.5 Market Breakdown and Data Triangulation
    2.6 Assumptions for the Study

3 Executive Summary
    3.1 Introduction

4 Premium Insights
    4.1 NGS-based RNA-seq Market Overview
    4.2 Market Growth Rate, By Technology, 2017 vs 2022 (USD Million)
    4.3 Market, By Application and Region, 2017 (USD Million)
    4.4 Market, By End User, 2017 vs 2022
    4.5 Geographical Snapshot of the Market

5 Market Overview
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Advantages of RNA-seq Over Microarray Technology
                    5.2.1.2 Technological Advancements in RNA-seq Products
                    5.2.1.3 Increasing Number of RNA-seq Grants
                    5.2.1.4 Increasing Number of Research Activities Involving RNA-seq
                    5.2.1.5 Rapid Growth in Precision Medicine
           5.2.2 Restraints
                    5.2.2.1 Lack of Skilled Professionals
                    5.2.2.2 Standardization Concerns of RNA-seq in Diagnostic Testing
           5.2.3 Opportunities
                    5.2.3.1 Increasing Applications of RNA-seq in Research
                               5.2.3.1.1 Cancer Research
                               5.2.3.1.2 Agricultural Research
           5.2.4 Challenges
                    5.2.4.1 Storage & Interpretation of Sequencing Data
                    5.2.4.2 Analysis of RNA-seq Data for Detection of Novel Transcripts
    5.3 Industry Trends
           5.3.1 Growing Number of Strategic Partnerships and Collaborations
           5.3.2 Increasing Number of Conferences and Workshops Related to RNA-seq

6 Global NGS-based RNA Sequencing Market, By Product & Service
    6.1 Introduction
           6.1.1 Sample Preparation
                    6.1.1.1 Sample Preparation, By Workflow Step
                               6.1.1.1.1 Fragmentation, End Repair, and Size Selection
                               6.1.1.1.2 Library Preparation and Target Enrichment
                               6.1.1.1.3 Quality Control
                    6.1.1.2 Sample Preparation, By Method
                               6.1.1.2.1 Manual Sample Preparation
                               6.1.1.2.2 Microfluidic Sample Preparation
                               6.1.1.2.3 Robotic Liquid Handling Sample Preparation
           6.1.2 Sequencing Platforms and Consumables
           6.1.3 Sequencing Services
           6.1.4 Data Analysis, Storage, and Management

7 Global NGS-based RNA Sequencing Market, By Technology
    7.1 Introduction
    7.2 Sequencing By Synthesis
    7.3 Ion Semiconductor Sequencing
    7.4 Single-Molecule Real-Time Sequencing
    7.5 Nanopore Sequencing

8 Global NGS-based RNA Sequencing Market, By Application
    8.1 Introduction
    8.2 Expression Profiling Analysis
    8.3 Small RNA Sequencing
    8.4 De Novo Transcriptome Assembly
    8.5 Variant Calling and Transcriptome Epigenetics

9 Global NGS-based RNA Sequencing Market, By End User
    9.1 Introduction
    9.2 Research Centers and Academic & Government Institutes
    9.3 Hospitals & Clinics
    9.4 Pharmaceutical & Biotechnology Companies
    9.5 Other End Users

10 Global NGS-based RNA Sequencing Market, By Region
     10.1 Introduction
     10.2 North America
             10.2.1 U.S.
             10.2.2 Canada
     10.3 Europe
     10.4 Asia-Pacific
     10.5 Rest of the World

11 Competitive Landscape
     11.1 Business Overview
     11.2 Vendor Inclusion Criteria
     11.3 Vendor Dive
             11.3.1 Vanguards
             11.3.2 Innovators
             11.3.3 Dynamic Players
             11.3.4 Emerging Players
     11.4 Competitive Benchmarking
             11.4.1 Product Offering (For All 25 Companies)
             11.4.2 Business Strategy (For All 25 Companies)

12 Company Profiles
     12.1 Illumina, Inc.
     12.2 Thermo Fisher Scientific Inc.
     12.3 Pacific Biosciences of California, Inc.
     12.4 Qaigen N.V.
     12.5 F. Hoffmann-La Roche AG
     12.6 Agilent Technologies, Inc.
     12.7 BGI (Beijing Genomics Institute)
     12.8 Oxford Nanopore Technologies, Ltd
     12.9 Perkinelmer, Inc.
     12.10 Eurofins Scientific
     12.11 Gatc Biotech AG
     12.12 Macrogen, Inc.

List of Tables
Table 1 Global NGS-based RNA-seq Market Snapshot (2017 vs 2022)
Table 2 Key RNA-seq Products Launched By Market Players (2015-2017)
Table 3 Global Market Size, By Product & Service, 2015-2022 (USD Million)
Table 4 Global Market Size, By Product & Service, By Region, 2015-2022 (USD Million)
Table 5 Global RNA-seq Sample Preparation Market Size, By Region, 2015-2022 (USD Million)
Table 6 Liquid Handling Systems: Key Products in the Market
Table 7 RNA-seq Platforms and Consumables Market Size, By Region, 2015-2022 (USD Million)
Table 8 RNA-seq Services Market Size, By Region, 2015-2022 (USD Million)
Table 9 RNA-seq Data Analysis, Storage, & Management Market Size, By Region, 2015-2022 (USD Million)
Table 10 Market Size, By Technology, 2015-2022 (USD Million)
Table 11 Market, By Region, 2015-2022 (USD Million)
Table 12 Market for Sequencing By Synthesis, By Region, 2015-2022 (USD Million)
Table 13 Market for Ion Semiconductor Sequencing, By Region, 2015-2022 (USD Million)
Table 14 Market for Single-Molecule Real-Time Sequencing, By Region, 2015-2022 (USD Million)
Table 15 Market for Nanopore Sequencing, By Region, 2015-2022 (USD Million)
Table 16 Market Size, By Application, 2015-2022 (USD Million)
Table 17 Market Size for Expression Profiling Analysis, By Region, 2015-2022 (USD Million)
Table 18 Market Size for Small RNA Sequencing, By Region, 2015-2022 (USD Million)
Table 19 Market Size for De Novo Transcriptome Assembly, By Region, 2015-2022 (USD Million)
Table 20 Market Size for Variant Calling and Transcriptome Epigenetics, By Region, 2015-2022 (USD Million)
Table 21 NGS-based RNA-seq Market Size, By End User, 2015-2022 (USD Million)
Table 22 Market Size for Research Centers and Academic & Government Institutes, By Region, 2015-2022 (USD Million)
Table 23 NGS-based RNA-seq Market Size for Hospitals & Clinics, By Region, 2015-2022 (USD Million)
Table 24 Market Size for Pharmaceutical & Biotechnology Companies, By Region, 2015-2022 (USD Million)
Table 25 Market Size for Other End Users, By Region, 2015-2022 (USD Million)
Table 26 Market Size, By Region, 2015-2022 (USD Million)
Table 27 North America: NGS-based RNA-seq Market Size, By Product & Service, 2015-2022 (USD Million)
Table 28 North America: Market Size, By Technology, 2015-2022 (USD Million)
Table 29 North America: NGS-based RNA-seq Market Size, By Application, 2015-2022 (USD Million)
Table 30 North America: Market Size, By End User, 2015-2022 (USD Million)
Table 31 Europe: NGS-based RNA-seq Market Size, By Product & Service, 2015-2022 (USD Million)
Table 32 Europe: Market Size, By Technology, 2015-2022 (USD Million)
Table 33 Europe: Market Size, By Application, 2015-2022 (USD Million)
Table 34 Europe: Market Size, By End User, 2015-2022 (USD Million)
Table 35 Asia-Pacific: NGS-based RNA-seq Market Size, By Product & Service, 2015-2022 (USD Million)
Table 36 Asia-Pacific: Market Size, By Technology, 2015-2022 (USD Million)
Table 37 Asia-Pacific: Market Size, By Application, 2015-2022 (USD Million)
Table 38 Asia-Pacific: Market Size, By End User, 2015-2022 (USD Million)
Table 39 RoW: NGS-based RNA-seq Market Size, By Product & Service, 2015-2022 (USD Million)
Table 40 RoW: Market Size, By Technology, 2015-2022 (USD Million)
Table 41 RoW: Market Size, By Application, 2015-2022 (USD Million)
Table 42 RoW:  Market Size, By End User, 2015-2022 (USD Million)

List of Figures
Figure 1 Global NGS-based RNA-seq Market: Research Methodology Steps
Figure 2 Breakdown of Supply-Side Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market: Bottom-Up Approach
Figure 4 NGS-based RNA-seq Market: Top-Down Approach
Figure 5 Market: Data Triangulation
Figure 6 Global NGS-based RNA-seq Market, By Products & Services, 2017-2022
Figure 7 Global Market, By Technology, 2017-2022 (USD Million)
Figure 8 Global Market, By Application, 2017 vs 2022
Figure 9 Global Market, By End User, 2017-2022 (USD Million)
Figure 10 Global Market, By Region, Market Share (2017) & CAGR (2017-2022)
Figure 11 Advantages of RNA-seq Over Microarray Technology are A Major Factor Driving the Growth of the NGS-based RNA-seq Market
Figure 12 Sequencing By Synthesis Technology to Hold Large Market Share During the Forecast Period
Figure 13 Expression Profiling Analysis to Command A Major Share of the NGS-based RNA-seq Market in 2017
Figure 14 Research Centers and Academic & Government Institutes to Dominate the Global NGS-based RNA-seq Market in 2017 and 2022
Figure 15 Asia-Pacific to Register the Highest CAGR During the Forecast Period (2017 to 2022)
Figure 16 NGS-based RNA-seq Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Global Funding Activities for RNA-seq and Microarray Projects, 2009-2016
Figure 18 Number of RNA-seq Publications Globally, 2011-2016
Figure 19 NGS-based RNA-seq Market, By Product & Service
Figure 20 Major Market Players in the RNA-seq Market
Figure 21 Major Steps in RNA-seq Sample Preparation
Figure 22 Library Preparation & Target Enrichment Segment Dominates the RNA-seq Sample Preparation Market in 2016
Figure 23 Nanopore Sequencing to Register the Highest CAGR During 2017 to 2022
Figure 24 Applications of NGS-based RNA-seq
Figure 25 Expression Profiling Analysis to Hold the Largest Share in the NGS-based RNA-seq Market in 2016
Figure 26 Expression Profiling Analysis Workflow
Figure 27 Small RNA Sequencing Workflow
Figure 28 Strategies for De Novo Transcriptome Assembly From RNA-seq Data
Figure 29 Variant Calling and Transcriptome Epigenetics for RNA-seq
Figure 30 Pharmaceutical & Biotechnology Companies to Register the Highest CAGR in the Forecast Period
Figure 31 Asia-Pacific to Grow at the Highest Rate During the Forecast Period
Figure 32 North America: NGS-based RNA-seq Market Snapshot
Figure 33 Europe: Market Snapshot
Figure 34 Asia-Pacific: NGS-based RNA-seq Market Snapshot
Figure 35 RoW: Market Snapshot
Figure 36 Vendor Dive: Evaluation Overview
Figure 37 Illumina, Inc.: Company Snapshot (2016)
Figure 38 Thermo Fisher Scientific: Company Snapshot (2016)
Figure 39 Pacific Biosciences of California, Inc.: Company Snapshot (2016)
Figure 40 Qaigen N.V.: Company Snapshot (2016)
Figure 41 F. Hoffmann-La Roche AG: Company Snapshot (2016)
Figure 42 Agilent Technologies, Inc.: Company Snapshot (2016)
Figure 43 Perkinelmer, Inc.: Company Snapshot (2016)
Figure 44 Eurofins Scientific: Company Snapshot (2016)
Figure 45 Macrogen, Inc.: Company Snapshot (2015)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 10x Genomics Inc. (U.S.)
  • BGI (China)
  • Gatc Biotech AG (Germany)
  • Genewiz Inc. (U.S.)
  • Hamilton Company (U.S.)
  • Illumina Inc. (U.S.)
  • MORE

The global NGS-based RNA-seq market is projected to reach USD 2.65 Billion by 2022 from USD 1.05 Billion in 2017, at a CAGR of 20.2% during the forecast period. The advantages of RNA-seq over microarray technology, technological advancements in RNA-seq products, increasing number of RNA-Seq grants, increasing number of research activities, and rapid growth in precision medicine are the key factors driving the growth of the market. On the other hand, lack of skilled professionals and standardization concerns of RNA-seq in diagnostic testing are some of the key factors limiting the growth of the market. The increasing applications of RNA-seq in research are expected to provide a wide range of growth opportunities for players in the market. Storage and interpretation of sequencing data and analysis of RNA-seq data for novel transcripts are expected to challenge market growth.

This report broadly segments the NGS based RNA-Seq market into products & services, technology, application, and end user. On the basis of product and service, the NGS market is categorized into sample preparation, sequencing platforms & consumables, sequencing services, and data analysis, storage, & management. In 2016, the sequencing platforms and consumables segment accounted for the largest share of the market.

On the basis of technology, the market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing. In 2016, the SBS technology accounted for the largest share of the market, majorly due to the development of new and advanced NGS platforms, the increasing demand for Illumina’s systems (including the HiSeq series and MiSeq), and the growing demand for NextSeq and HiSeq X Ten.

Based on applications, the market is categorized into four segments, namely, de novo transcriptome assembly, small RNA sequencing, expression profiling analysis, and variant calling & transcriptome epigenetics. The expression profiling analysis segment accounted for the major share of the market and expected to register the highest growth during the forecast period.

On the basis of end user, the market is segmented into research centers and academic & government institutes, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users. Among these end users, the hospitals and clinics segment is expected to register the highest CAGR due to the growing number of agreements between companies and hospitals for the development of advanced tests and products catering to the specific needs of hospitals and clinics. For instance, in February 2016, Thermo Fisher Scientific and Children's Hospital Los Angeles (CHLA, U.S.) collaborated to develop a targeted RNA & DNA sequencing-based research gene-panel specifically for pediatric cancer.

This report covers the NGS market across four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Of the four geographic regions studied in the report, North America is commanded the largest share of the market in 2016. However, Asia-Pacific is expected to register the highest growth rate during the forecast period, due to increasingly focus of key market players on strengthening their presence in the Asia-Pacific region. Globaly, the market growth is expected to be hindered by lack of skilled RNA-seq professionals across the globe.

The major players in the global market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N. V. (Germany), Pacific Biosciences of California, Inc. (U.S.), BGI (China), Oxford Nanopore Technologies, Ltd. (U.K.), PerkinElmer, Inc. (U.S.), GATC Biotech AG (Germany), Agilent Technologies, Inc. (U.S.), Roche Holding AG (Switzerland), Macrogen, Inc. (South Korea), and Eurofins Scientific (Luxembourg).

Illumina Inc. dominates the market through its wide range of technologically advanced and innovative platforms and associated RNA-seq products. The company adopts the strategy of product launches and company invests a significant amount of its revenue on R&D expenditure to maintain its leadership position in the market. For instance, in 2016, the company invested 21.0% of its revenue on R&D, as compared to 18.1% in 2015. The inorganic growth strategy includes strategic agreements with leading players in the market for the development of advanced technologies and strengthening of its research and commercialization capabilities. With its strong product portfolio and wide geographic presence, the company is expected to maintain its dominance in the market during the forecast period.

Thermo Fisher Scientific is another leading market player that offers extensive range of NGS-based RNA-seq products such as analytical instruments, equipment, reagents and consumables, and software & services. It entered the market through the acquisition of Life Technologies in 2014. The company adopts various organic and inorganic strategies such as agreements with leading pharmaceutical companies, for the development of NGS-based oncology tests for companion diagnostics. With its strong geographic presence and robust product portfolio, the company is expected to witness rapid growth in the market.

Note: Product cover images may vary from those shown
5 of 5
  • 10x Genomics Inc. (U.S.)
  • Agilent Technologies (U.S.)
  • BGI (China)
  • Bio-Rad Laboratories Inc. (U.S.)
  • Biomatters Ltd. (New Zealand)
  • Cofactor Genomics Inc. (U.S.)
  • Eurofins Scientific (Luxembourg)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Gatc Biotech AG (Germany)
  • Genewiz Inc. (U.S.)
  • Hamilton Company (U.S.)
  • Illumina Inc. (U.S.)
  • Intrexon Corp. (U.S.)
  • Macrogen Inc. (South Korea)
  • Medgenome Inc. (U.S.)
  • Novogene Corporation (China)
  • Nugen Technologies Inc. (U.S.)
  • Otogenetics Corporation (U.S.)
  • Oxford Nanopore Technologies (U.K.)
  • Pacific Biosciences of California Inc. (U.S.)
  • Perkinelmer Inc. (U.S.)
  • Personalis Inc. (U.S.)
  • Qaigen N.V. (Germany)
  • Takara Holdings Inc. (Japan)
  • Thermo Fisher Scientific (U.S.)
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll